[What can be expected from the GLP-1 agonists and DPP-4 inhibitors in the treatment of type 2 diabetes?].
The GLP-1 agonists and DPP-4 inhibitors are two novel drug classes in the treatment of type 2 diabetes. They increase insulin secretion and inhibit glucagon secretion without risk of hypoglycaemia. A decrease of glycated haemoglobin of about 1% can be expected with their use as monotherapy and as add-on therapy to the usual oral antidiabetics. In addition, GLP-1 agonists induce weight reduction at the price of gastro-intestinal side-effects and the need for subcutaneous administration. DPP-4 inhibitors can be taken orally, are well-tolerated, but weight-neutral. In the absence of relevant clinical studies, their long-term efficacy is currently unknown, as well as the clinical impact of other promising effects like beta-cell preservation.
Egli
M
M
Service d'endocrinologie, diabétologie et métabolisme CHUV, 1011 Lausanne.
Ruiz
J
J
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*
D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D052216:Glucagon-Like Peptide 1